Clinicopathological significance of G9A expression in colorectal carcinoma

JIAN QIN¹*, ZHI ZENG²*, TAO LUO³, QINGYUN LI¹,¼, YARONG HAO⁴ and LANG CHEN⁵

¹Central Laboratory; ²Department of Pathology, Wuhan University, Renmin Hospital, Wuhan, Hubei 430060; ³Department of Anesthesiology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036; ⁴Department of Geriatrics, Wuhan University, Renmin Hospital, Wuhan, Hubei 430060; ⁵Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China

Received October 20, 2015; Accepted March 28, 2017

DOI: 10.3892/ol.2018.8446

Abstract. G9A, the primary histone methyltransferase (HMTase) for histone H3 lysine 9, is upregulated in numerous types of cancer and is critical for tumor cell proliferation. The present study aimed to investigate the G9A expression level in colorectal carcinoma (CRC) to evaluate the clinical significance of G9A in CRC. First, the present study detected the expression of G9A protein in 100 pairs of CRC specimens by immunohistochemistry staining and analyzed the correlations between G9A expression and pathological tumor features. It was found that G9A expression was increased markedly in CRC tumor specimens and the high expression was associated with tumor distant metastasis. Oncomine database analysis demonstrated an elevated expression level of G9A in various types of CRC. In total, 6 public available data sets from the Gene Expression Omnibus (GEO) were used and Gene set enrichment analysis (GSEA) was conducted. The results of the bioinformatics analysis demonstrated that high G9A expression was associated with American Joint Committee on Cancer staging, tumor differentiation, tumor relapse of CRC, and may serve a role in CRC cell proliferation. These findings suggested that G9A was overexpressed in CRC and involved in the tumorigenesis and distant metastasis of CRC. The expression level may also serve as a potential indicator for tumor recurrence in CRC. The present findings aided in the understanding of the crucial role of G9A in tumorigenesis and also offered novel ideas for CRC therapy.

Introduction

Aberrant epigenetic regulations have been found in various types of cancer and numerous types of human disease. The cancer epigenome is characterized by global changes in DNA methylation and altered histone modification patterns (1). The global pattern of histone modifications may serve as a predictor for the risk of recurrence of human cancers (2,3). It seems that epigenetics have reached the mainstream in pathogenesis research of numerous types of human disease, particularly in cancer. Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world (4). Cumulative evidence has proved that the disruption of epigenetic regulation may drive the initiation and progression of CRC, such as histone modifications (5-7). Emerging evidences reveal that altered expression of histone methyltransferases (HMTs) and histone demethylases (HDMs) may be involved in cancer progression of CRC, such as Enhancer of zeste homolog 2 (EZH2) and lysine demethylase 4C (5,8,9). The functions of HMTs and HDMs in the pathogenesis of CRC require further investigation.

G9A is the primary HMT for mono- and dimethylation of H3K9 in vivo (10). Among various best-studied histone methylations, H3K9 methylation is thought to be associated with gene repression (11). Recently, G9A has been reported to perform critical roles in a number of biological processes, such as behavior plasticity, lymphocyte development, stem cells differentiation and tumor cell growth (12-17). It has been found that the expression level of G9A is increased in numerous types of cancer as compared with their corresponding normal tissues, such as melanoma, lung cancer, neuroblastoma, leukemia and hepatocellular carcinoma (HCC) (17-19). It has been demonstrated that decreasing G9A expression level or inhibiting its activity reduces cellular proliferation and induces autophagy related cell death in colon cancer cells, breast cancer cells and neuroblastoma cells (17,20,21). A recent study also reported that G9A suppression induces DNA damage in colorectal cancer cells (21).

Correspondence to: Dr Jian Qin, Central Laboratory, Wuhan University, Renmin Hospital, 238 Jiefang Road, Wuhan, Hubei 430060, P.R. China
E-mail: qinjian621@163.com

Dr Lang Chen, Department of Immunology, School of Basic Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan, Hubei 430071, P.R. China
E-mail: langchen@whu.edu.cn

*Contributed equally

Key words: G9A, colorectal carcinoma, tumorigenesis, distant metastasis
Although G9A has been reported to be crucial in numerous types of cancer, the function in colorectal cancer progression remains unknown. In the present study, the expression profile of G9A in CRC was examined to explore the function in CRC progression. The immunohistochemistry analysis of 100 pairs of tumor specimens revealed that G9A protein expression was markedly increased in CRC and the high expression may be related to distant metastasis. A significant elevated mRNA expression level of G9A in various colorectal carcinomas compared with normal colon and rectum tissues by Oncomine database analysis was also identified. Furthermore, the present study investigated the association between G9A expression level and the clinicopathological features of CRC using 6 publicly available datasets from Gene Expression Omnibus (GEO), and found that G9A expression was associated with American Joint Committee on Cancer (AJCC) staging, tumor differentiation, and tumor relapse. The present findings provide novel evidence to further understand the crucial role of G9A in tumorigenesis, and also offers significant ideas for CRC therapy.

Materials and methods

Patients. In total, 100 patients were diagnosed with CRC (53 with colon cancer and 47 with rectal cancer; Table I), which was classified with the 7th edition of the International Union against Cancer TNM staging system (classified into T1, T2, T3 and T4 based on the size and the extension of the primary tumor; classified into N0, N1 and N2 based on the degree of spread to regional lymph nodes; classified into M0 and M1 based on the presence of distant metastasis), the Dukes' staging system (classified into A, B, C and D) and histological grading (classified into well, moderately, or poorly differentiated) (22-24). All patients underwent surgical resection of tumors at the Renmin Hospital of Wuhan University in Wuhan, China. Ethical approval for the study was granted by the Renmin Hospital's ethics committee. Informed written consent was obtained from all participants involved in the study. The key clinical characteristics of the patients are summarized in Table I. Normal specimens were obtained from adjacent, grossly normal-appearing tissue taken at least 10 cm away from the cancer. None of the patients included in this study had chemotherapy or radiotherapy prior to surgery. There was no follow-up information available for these patients.

Immunohistochemistry. Immunostaining was performed as described previously (25). Briefly, deparaffinized sections were treated with 3% H2O2 and subjected to antigen retrieval by citric acid (pH 6.0). Subsequently to overnight incubation with primary antibody of G9A (1:100; cat. no. ab133482; Abcam, Cambridge, UK) at 4°C, the sections were incubated for 15 min at room temperature with horseradish peroxidase-labeled polymer conjugated with secondary antibody (MaxVision™ HRP-Polymer anti-Rabbit IHC Kit; Maixin-Bio, Fuzhou, China) and incubated for 1 min with diaminobenzidine. The sections were then lightly counterstained with hematoxylin. The sections without primary antibody served as negative controls. The positive brown staining was visualized and then photographed using a light microscope at x200 or x400 magnification (BX51, Olympus Corporation, Tokyo, Japan).

Evaluation of immunohistochemical staining. The immunohistochemical staining results of all sections were evaluated by two independent observers (Dr Zhi Zeng and Dr Jian Qin, the co-authors), who were unaware of the disease outcome. Expression levels were ascertained according to the two observers' evaluations. As G9A is mainly expressed in the cell nucleus, the percentage of nucleus staining-positive cells were graded as 0 (<10%), 1 (≥10%, and <25%), 2 (≥25%, and <50%), 3 (≥50%, and <75%), 4 (≥75%) (Fig. 1A-F). For analysis the G9A protein expression levels were divided into two groups: Low expression level group (score value ≤2) and high expression level group (score value ≥3).

Oncomine database analysis. The Oncomine database (https://www.oncomine.org) (26), which is a cancer microarray database and web-based data-mining platform, was interrogated to validate the expression status of G9A mRNA in various types of CRC. Filter indexes were set in Oncomine based on research interests. Primary filters were set as differential analysis (cancer vs. normal) and cancer type (colorectal cancer). Dataset filters were set as data type (mRNA). Datasets were ordered by overexpression with P-value. Datasets were set by P-value (1E-6) and fold change (1.5+). The datasets were then sorted to analyze the expression of G9A mRNA associated with different cancer types vs. normal tissue.

Publicly available data analysis. The data sets of the patients with CRC and the corresponding clinical data were downloaded from the publicly available Gene Expression Omnibus (GEO) datasets (http://www.ncbi.nlm.nih.gov/gds; National Center for Biotechnology Information, Bethesda, USA). A total of 6 independent data sets from GSE38832 (27) (n=122), GSE37892 (28) (n=130), GSE28722 (29) (n=125), GSE17536 (30,31) (n=177), GSE18088 (32) (n=53), and GSE33113 (33,34) (n=96) were utilized to analyze the expression level of G9A in CRC. The patients were divided into two groups according to their G9A expression level (top 50%, high vs. bottom 50%, low). For GSE38832, GSE37892, GSE17536, GSE18088 and GSE33113, Log2 intensity of probe 10023819278 and GSE6988, Log2 intensity of probe 10023819278 and AA434117 were used to represent the expression level of G9A. For GSE28722 and GSE6988, Log2 intensity of probe 10023819278 and AA434117 were used to represent the expression level of G9A, respectively. The significance was defined as P<0.05.

Gene set enrichment analysis (GSEA). JAVA program for GSEA (http://www.broadinstitute.org/gsea) (35,36) was utilized to analyze the potential genes influenced by G9A high expression. CRC patient gene profiling data (GSE37892 and GSE18088) was obtained from the GEO site. The patients were divided into two groups according to their G9A expression level (top 50%, high vs. bottom 50%, low) and GSEA was carried out to assess the effects of G9A expression level on various biological gene sets. MsigDB c5 (GO gene sets, 1,454 gene sets) was used. Gene sets with a false discovery rate value (FDR) of <0.25 and normal values of P<0.05 subsequent to performing 1,000 permutations were regarded as having significant enrichment.
Statistical analysis. Experimental data were analyzed with SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA). The χ² and Fisher’s exact tests were used to analyze the statistical significance of the relationship between G9A expression and the clinicopathological features. For univariate recurrence analysis, recurrence curves were obtained with the Kaplan-Meier method and compared using the log-rank test. P<0.05 was considered to represent a statistically significant difference.

Results

G9A expression was increased in CRC tumor tissues. To investigate the role of G9A in colorectal cancer, we examined G9A protein expression level in 100 pairs of colorectal cancer tissues and the corresponding non-cancerous tissues by immunohistochemistry. G9A positively staining cells exhibited brown particles that localized in nuclei (Fig. 1A-G). Results showed that G9A protein expression was significantly increased

| Clinicopathological features | Case size, n | Low, n (%) | High, n (%) |
|-----------------------------|--------------|------------|-------------|
| Diagnosis age (years)       |              |            |             |
| ≤60                         | 49           | 22 (44.90) | 27 (55.10)  |
| >60                         | 51           | 34 (66.67) | 17 (33.33)  |
| Sex                         |              |            |             |
| Male                        | 50           | 28 (56.00) | 22 (44.00)  |
| Female                      | 50           | 28 (56.00) | 22 (44.00)  |
| Size (diameter)             |              |            |             |
| <5 cm                       | 47           | 24 (51.06) | 23 (48.94)  |
| ≥5 cm                       | 53           | 32 (60.38) | 21 (39.62)  |
| Depth of invasion           |              |            |             |
| T1                          | 13           | 8 (61.54)  | 5 (38.46)   |
| T2                          | 42           | 24 (57.14) | 18 (42.86)  |
| T3                          | 35           | 22 (62.86) | 13 (37.14)  |
| T4                          | 10           | 2 (20.00)  | 8 (80.00)   |
| Nodal metastasis            |              |            |             |
| N0                          | 57           | 33 (57.89) | 24 (42.11)  |
| N1                          | 23           | 12 (52.17) | 11 (47.83)  |
| N2                          | 18           | 9 (50.00)  | 9 (50.00)   |
| Distant metastasis          |              |            |             |
| M0                          | 89           | 53 (59.55) | 36 (40.45)  |
| M1                          | 11           | 3 (27.27)  | 8 (72.73)   |
| TNM stage                   |              |            |             |
| I                           | 13           | 8 (61.54)  | 5 (38.46)   |
| II                          | 42           | 24 (57.14) | 18 (42.86)  |
| III                         | 35           | 22 (62.86) | 13 (37.14)  |
| IV                          | 10           | 2 (20.00)  | 8 (80.00)   |
| Dukes stage                 |              |            |             |
| A                           | 14           | 9 (64.29)  | 5 (35.71)   |
| B                           | 41           | 23 (56.10) | 18 (43.90)  |
| C                           | 34           | 21 (61.76) | 13 (38.24)  |
| D                           | 11           | 3 (27.27)  | 8 (72.73)   |
| Differentiation             |              |            |             |
| Well                        | 20           | 13 (65.00) | 7 (35.00)   |
| Moderately                  | 57           | 30 (52.63) | 27 (47.37)  |
| Poorly                      | 23           | 13 (56.52) | 10 (43.48)  |

*aChi-square test was used to statistically analyze the association between title category and G9A protein expression (all unmarked P-values); bCompared with TNM stage IV; cCompared with Dukes stage C.
QIN et al: CLINICOPATHOLOGICAL SIGNIFICANCE OF G9A IN CRC

8614

in tumor samples (44%, n=100) in comparison to that in the adjacent non-cancer tissue samples (8.54%, n=82) (Fig. 1H). The difference was significant (P<0.05). In Fig. 1G, the represented specimen was from the junction between tumoral and non-tumoral tissue. As illustrated in Fig. 1G, G9A protein is strongly stained in the tumoral region, whereas the non-tumoral region is weakly stained. The present results indicate that G9A expression in CRC tumor samples is significantly higher than that in adjacent noncancerous tissue samples (Fig. 1H; P<0.05).

Association between G9A expression and clinicopathological features of CRC. The present study analyzed the association of G9A protein expression level with patient age, gender, size, TNM stages (primary tumor status (T1-T4), nodal metastasis (N0-N2), distant metastasis), Dukes stages (A-D), and histological grade (well, moderately, or poorly differentiated) in the CRC samples (Table I). There were significant differences in the G9A protein expression levels between later the TNM stage and the other TNM stages (P=0.035, P=0.020; IV compared with II and III, respectively; Table I, Fig. 2A). In addition, expression of G9A in tumor with distant metastasis was increased compared with that without distant metastasis (P=0.043, Table I, Fig. 2B). It also demonstrated a weak association with Dukes Stage that G9A expression in Dukes stage D tumor was significantly increased compared with that in Dukes stage C tumor (P=0.049; Table I, Fig. 2C). There was no significant correlation of G9A expression with other clinicopathological features, such as patient age, gender, tumor size, invasion and nodal metastasis.

Expression of G9A using online analysis platform. The present study explored the mRNA expression level of G9A
in CRC. Data mining and analysis of G9A mRNA expression level from the publicly available Oncomine database was performed. The threshold was set by the P-value (1E-6) and by fold change (1.5+). There were 4 data sets that met the requirements, which were the TCGA (The Cancer Genome Atlas) colorectal cancer dataset consisting of 237 clinical samples, the Kaiser colon dataset consisting of 105 clinical samples, the Gaedcke colorectal dataset consisting of 130 clinical samples and the Hong colorectal dataset consisting of 82 samples. The results from Oncomine further confirmed the significantly higher expression level of G9A identified in various colorectal carcinomas, such as cecum adenocarcinoma, colon adenocarcinoma, colon mucinous adenocarcinoma and rectal adenocarcinoma (Fig. 3A-C). The corresponding P-values and fold changes are exhibited in Fig. 3D-F, respectively. These results indicated that G9A mRNA expression was increased in CRC tumor tissues.

Association between G9A mRNA expression and clinicopathological features of colorectal cancer. To figure out the relationships between elevated G9A expression level and the clinicopathological features of CRC, the present study chose 5 GEO datasets with corresponding clinical information

| Legend code | Cancer/Noraml type | Case number | P-value | Fold change |
|-------------|--------------------|-------------|---------|-------------|
| 1           | Normal rectum or colon | 22          |        | /           |
| 2           | Cecum adenocarcinoma vs. Normal | 22   | 9.40E-13 | 2.064 |
| 3           | Colon adenocarcinoma vs. Normal | 101  | 4.73E-13 | 1.955 |
| 4           | Colon mucinous adenocarcinoma vs. Normal | 22   | 1.14E-7  | 1.594 |
| 5           | Rectal adenocarcinoma vs. Normal | 60   | 1.74E-13 | 1.981 |
| 6           | Rectal mucinous adenocarcinoma vs. Normal | 6    | 5.29E-5  | 1.578 |

| Legend code | Cancer/Noraml type | Case number | P-value | Fold change |
|-------------|--------------------|-------------|---------|-------------|
| 1           | Normal           | 5           |        | /           |
| 2           | Cecum adenocarcinoma vs. Normal | 17   | 2.99E-6  | 1.571 |
| 3           | Colon adenocarcinoma vs. Normal | 41   | 1.33E-5  | 1.572 |
| 4           | Colon mucinous adenocarcinoma vs. Normal | 13   | 2.99E-7  | 1.652 |
| 5           | Rectosigmoid adenocarcinoma vs. Normal | 10   | 3.66E-6  | 1.747 |

Figure 3. The box plots were downloaded from ONCOMINE. Integrative analysis of G9A overexpression in colorectal cancer vs. normal colorectal type. (A) Box plots exhibiting relative G9A expression levels in TCGA colorectal cancer datasets grouped by cancer and normal tissue. Numbers 1-6 represent different cancer/normal types described in (D). (B) Box plots exhibiting relative G9A expression levels in Kaiser Colon dataset grouped by cancer and normal tissue. Numbers 1-5 represent different cancer/normal types described in (E). (C) Box plots exhibiting relative G9A expression in Gaedcke Colorectal dataset grouped by cancer and normal tissue. Numbers 1 and 2 represent different cancer/normal types described in (F). (D) Comparison of G9A expression levels in different cancer types vs. normal colorectal tissue in the TCGA colorectal cancer datasets. (E) Comparison of G9A expression levels in different cancer types vs. normal colorectal tissue in the Kaiser Colon dataset. (F) Comparison of G9A expression levels in different cancer types vs. normal colorectal tissue in the Gaedcke Colorectal dataset. P-values represent the differences between two group comparisons. Fold change represents the fold difference in G9A overexpression in cancer tissue vs. normal tissue. TCGA, The Cancer Genome Atlas.

Figure 4. The Kaplan-Meier method was used to estimate survival curves for GSE33113. Log-rank test was used to compare the differences between curves. The top 50% samples with the higher expression were considered as the high-expression group (H), and the remaining 50% of the samples as the low-expression group (L). P=0.0507.
for further analysis (Table II). The results demonstrated that G9A expression was associated with AJCC staging (P=0.027) and tumor cell differentiation (P=0.012) in GSE17536 (n=177), and it was also related with cancer relapse in GSE18088 (P=0.045, n=53). In GSE33113 (n=96), a marked association between G9A expression and the recurrence rate in CRC was found (P=0.0507, Fig. 4). It might suggest that CRC patients with high expression level of G9A were more likely to suffer relapse. However, cause the result based on GSE33113 was borderline significant (P=0.0507), this result still requires further investigation to further verify, as the association in this dataset did not prove to be statistically significant. No other associations between G9A expression and clinicopathological features in any other CRC datasets we found, including metastasis, staging, location or survival rate.

**G9A expression level associated with proliferation of CRC cells.** The G9A expression level was found consistently increased in both public available datasets and in

Table II. Correlation between G9A mRNA expression and the clinicopathological features of the CRC.

| Datasets      | Characteristic | Case size | G9 expression | P-value |
|---------------|----------------|-----------|---------------|---------|
| GSE38832      | Ajcc staging   |           |               |         |
| Probe: 202326 | 1              | 18        | High 7       | 0.259   |
|               | 2              | 35        | Low 17       |         |
|               | 3              | 39        | Low 25       |         |
|               | 4              | 30        | Low 14       |         |
| GSE28722      | Duke's staging |           |               |         |
| Probe: 10023819278 | A | 3 | High 1 | 0.618 |
|               | B             | 83        | Low 38       |         |
|               | C             | 34        | Low 12       |         |
|               | D             | 5         | Low 3        |         |
|               | Metastasis    |           |               | 0.916   |
|               | Y             | 33        | Low 14       |         |
|               | N             | 92        | Low 40       |         |
| GSE17536      | Ajcc staging   |           |               |         |
| Probe: 202326 | 1              | 24        | High 7       | 0.162   |
|               | 2              | 57        | Low 32       | 0.027   |
|               | 3              | 57        | Low 29       |         |
|               | 4              | 39        | Low 18       |         |
| GSE18088      | Relapse        |           |               |         |
| Probe: 202326 | Y              | 13        | Low 10       | 0.045   |
|               | N              | 40        | Low 18       |         |
| Gene expression classification into either low or high groups was determined by whether the value was lower or higher than the mean of that dataset. Chi-square test was used to statistically analyze the association between title category and G9A protein expression (all unmarked P-values); AJCC, American Joint Committee on Cancer.
the present CRC tumor samples. A GSEA analysis was conducted to investigate the potential biological processes that G9A high expression may influence. The results from GSEA using GSE37892 demonstrated that gene sets differences in G9A high vs. low patients indicated that G9A regulated gene sets mainly associated with DNA replication (P=0.016, FDR=0.160, Fig. 5A). The result by analyzing GSE18088 also indicated that high expression of G9A regulated gene sets associated with mitosis, although the FDR value was weak (M phase, P=0.042, FDR=0.433; mitosis, P=0.040, FDR=0.442; Fig. 5B and C). The present study concluded that G9A may be important for proliferation of CRC cells.

Discussion

The present study investigated the clinicopathological significance of G9A expression in CRC progression. Immunohistochemistry was performed to explore G9A protein expression pattern in 100 pairs of CRC samples. Combined with the results of the bioinformatics analysis, it was demonstrated that G9A expression was increased in CRC and that it is therefore involved in the carcinogenesis of CRC.

G9A is the primary histone lysine methyltransferase of lysine 9 on histone H3. Various studies have demonstrated that G9A is critical for numerous biological progresses, such as embryo development, behavior plasticity, lymphocyte development, stem cell differentiation and tumor cell growth (13,16,17,41). It has been reported as overexpressed in numerous types of cancer, including hepatocellular carcinoma, bladder cancer, leukemia and lung cancer (42). Inhibition of G9A represses cellular proliferation by inducing autophagy related cell death in colon cancer, breast cancer and neuroblastoma cells (17,20). The present study investigated the potential functions of G9A in CRC progression.

The results of the present immunohistochemistry analysis were consistent with Oncomine datasets, demonstrating that G9A expression was significantly elevated in CRC tumor tissues. Fig. 1G exhibited clearly that G9A was strongly stained in the tumor region and weakly stained in the non-tumor region. The clinical significance of high G9A expression in CRC was further analyzed. It was found that G9A protein expression was significantly higher in TNM stage IV tumor than any other TNM stages in our 100 specimens. In addition, the G9A expression exhibited a higher expression in Dukes stage D tumor than that in stage C tumor, and also a higher expression in tumor with distant metastasis than that without distant metastasis. According to the principle of all these different types of staging methods, G9A expression levels may be important for the metastasis status of CRC. A previous study on lung cancer has stated that G9A has the ability to promote tumor invasion and metastasis in lung cancer (43). The present study provided the evidence that increased expression of G9A was associated with metastasis in CRC. In accordance, by using publicly available datasets from GEO, it was found that high G9A expression was associated with AJCC staging and differentiation of CRC in one of the datasets analyzed. However, since the results were not consistent among different datasets used, and the association between G9A expression and tumor relapse in CRC was borderline significant, the associations between G9A and tumor metastasis or tumor recurrence need to be further confirmed.

To find the potential function of G9A in CRC progression, GSEA analysis was performed. The results demonstrated that G9A was significantly associated with DNA replication and mitosis in CRC tumor cells in 2 datasets analyzed. These results strongly indicated that G9A was important for colorectal cancer cell proliferation, which was consistent with the previous research (20). It has been demonstrated that G9A inhibition represses proliferation in colon cancer HCT116 cells and numerous other types of cancer cell (20,21). The present study suggested that high expression level of G9A was critical for CRC tumorigenesis.

In the present study, the clinicopathological significance of G9A high expression in CRC was discussed. In conclusion, the results suggested that G9A expression was increased in CRC tumor samples and the high expression was important for tumorigenesis. Evidence that G9A high expression may be important for distant metastasis in CRC has been provided. The findings helped to further understand the crucial role of G9A in tumorigenesis, and also offered significant ideas for CRC therapy.
Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Foundation of China (grant no. 31300609), the Natural Science Foundation of Hubei Province in China (grant nos. 2012FFB04316 and 2013CFFB255) and The Incubator Project of Renmin Hospital Wuhan University (grant no. 2013RMFH008).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
JQ and ZZ analyzed and interpreted the patient data. ZZ, QL and YH collected the samples. TL contributed to data analysis and the manuscript drafting. JQ and LC contributed to the study design and manuscript writing.

Ethics approval and consent to participate
Ethical approval for the study was granted by the Renmin Hospital's ethics committee. Informed written consent was obtained from all participants involved in the study.

Consent for publication
Informed written consent for publication was obtained from all participants involved in the study.

Competing interests
The authors declare that they have no competing interests.

References
1. Rodríguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339, 2011.
2. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrini K, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
3. Wood L,D, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Pukj J, et al: The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113, 2007.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
5. Carmona FJ and Esteller M: Moving closer to a prognostic DNA methylation signature in colon cancer. Clin Cancer Res 17: 1215-1217, 2011.
6. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186, 2009.
7. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13: 529-541, 2008.
8. Fluge O, Grøvdal K, Carlens E, Vonen B, Kjellvedol K, Refsum S, Lillegaard TJ, Sjovold TN, Tveit KM, et al: Expression of EZH2 and K1-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101: 1282-1289, 2009.
9. Yamamoto S, Tatsishi K, Kudo Y, Yamamoto K, Iwagao T, Nagae G, Nakatsuka T, Asaoka Y, Iijishi H, Hizata Y, et al: Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colon cancer cells. Carcinogenesis 34: 2380-2388, 2013.
10. Shinkai Y and Tachibana M: H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 25: 781-788, 2011.
11. Dawson MA and Kouzartides T: Cancer epigenetics: From mechanism to therapy. Cell 150: 12-27, 2012.
12. Maze I, Covington HE III, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, et al: Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 327: 213-216, 2010.
13. Thomas LR, Miyashita H, Cobb RM, Pierce S, Tachibana M, Hobeika E, Reth M, Shinkai Y and Oltz EM: Functional analysis of histone methyltransferase g9a in B and T lymphocytes. J Immunol 181: 485-493, 2008.
14. Katoh K, Yamazaki R, Onishi A, Sanuki R and Furukawa T: G9a histone methyltransferase activity in retinal progenitors is essential for proper differentiation and survival of mouse retinal cells. J Neurosci 32: 17658-17670, 2012.
15. Ueda J, Ho JC, Lee KL, Kijatjima S, Yang H, Sun W, Fukuhara N, Zaiden N, Chan SL, Tachibana M, et al: The hypoxia-inducible epigenetic regulators Jmdj1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Mol Cell Biol 34: 3702-3720, 2014.
16. Chen X, Skutt-Kakaria K, Davison J, Ou YL, Choi E, Malik P, Loeb K, Wood B, Georges G, Tokor-Storb B and Padison PJ: G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev 26: 2499-2511, 2012.
17. Ke XX, Zhang D, Zha S, Xia Q, Xiang Z and Cui H: Inhibition of H3K9 methyltransferase G9a repressed cell proliferation and induced autophagy in neuroblastoma cells. PLoS One 9: e106962, 2014.
18. Huang J, Dorsey J, Chuiikov S, Perez-Burgos L, Zhang X, Jengwein T, Reinberg D and Berger SL: G9a and Glp methyllysine lysine 373 in the tumor suppressor p53. J Biol Chem 285: 9636-9641, 2010.
19. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugach F, et al: Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37: 974-983, 2007.
20. Kim Y, Kim YS, Kim DE, Lee JS, Song JH, Kim HG, Cho DH, Jeong SY, Jin DH, Jang SJ, et al: BIX-01294 induces autophagy-associated cell death via EMTZ/G9a dysfunction and intracellular reactive oxygen species production. Autophagy 9: 2126-2139, 2013.
21. Zhang J, He P, Xi Y, Geng M, Chen Y and Ding J: Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget 6: 2917-2927, 2015.
22. Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
23. Kyriakos M: The President's cancer, the Dukes classification, and confusion. Arch Pathol Lab Med 109: 1063-1066, 1985.
24. Barresi V, Reggiani Bonetti L, Ieni A, Caruso RA and Tucciari C: Histological grading in colorectal cancer: An analysis of 371 cases based on tumoral histological, clinical and biological findings. Histol Histopathol 30: 1059-1067, 2015.
25. Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, Wang P and Fu GH: Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol 35: 3845-3853, 2014.
26. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Nucleic Acids Res 6: 1-6, 2004.
27. Tripathi MK, Deneau NG, Zhu J, An H, Mima S, Wang X, Padmanabhan S, Shi Z, Produttori N, Ciombor KK, et al: Nuclear factor of activated T-cell activity is associated with metastatic cancer. Carcinogenesis 34: 6947-6957, 2014.
28. Laibe S, Lagarde A, Ferrari A, Monges G, Birnbaum D and Gori JC: COL2 project: A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III. OMICS 16: 560-565, 2012.
target genes predicts poor prognosis in colorectal cancer patients

Bergh SP, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den de Sousa e Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, Kemper K, Versloot M, Cameron K, Beckmann G, Sommer A, Grützmann R, Pilarsky C, Gröne J, Lenze D, Jurinovic V, Hummel M, Seidel H, Leder G, Beckmann G, Sommer A, Grützmann R, Pilarsky C, et al: Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis 26: 847-858, 2011.

Kemper K, Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J and Medema JP: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res 18: 3132-3141, 2012.

de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuyman JB, Prasetyanti PR, Fessler E, van den Bergh SP, et al: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 9: 476-485, 2011.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273, 2003.

Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337, 2012.

Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, et al: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131, 2007.

Gaedeke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 49: 1024-1034, 2010.

Hong Y, Downey T, Eu KW, Koh PK and Cheah PY: A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 27: 83-90, 2010.

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Okhi M, Fukuda M, Takeda N, Niida H, Kato H and Shinkai Y: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 16: 1779-1791, 2002.

Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, Tsunoda T, Field HI, Neal DE, Ponder BA, et al: Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13: 676-684, 2011.

Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, et al: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 70: 7830-7840, 2010.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.